Akt/PKB activation in gastric carcinomas correlates with clinicopathologic variables and prognosis

APMIS

Volumn 111, Issue 12, 2003, Pages 1105-1113

  Nam, Seon Young ^a   Lee, Hye Seung ^a   Jung, Gyung Ah ^a   Choi, Jimi ^a   Cho, Sung Jin ^a   Kim, Min Kyu ^a   Kim, Woo Ho ^a   Lee, Byung Lan ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

Akt; Gastric carcinoma; pAkt; Prognosis

Indexed keywords

PROTEIN KINASE B;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVATION; EVALUATION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CARCINOMA;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SMAD4 PROTEIN; STOMACH NEOPLASMS; SURVIVAL RATE; TRANS-ACTIVATORS;

EID: 0346494938     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2003.apm1111205.x     Document Type: Article

References (41)

1. Saegusa M, Takano Y, Kamata Y, Okayasu J. Bcl-2 expression and allelic loss of the p53 gene in gastric carcinomas. J Cancer Res Clin Oncol 1996;122:427-32.
2. Wu LB, Kushima R, Borchard F, Molsberger G, Hattori T. Intramucosal carcinomas of the stomach. Phenotypic expression and loss of heterozygosity at microsatellites linked to the APC gene. Pathol Res Pract 1998;194:405-11.
3. Endoh Y, Sakata K, Tamura G, Ohmura K, Ajioka Y, Watanabe H, et al. Cellular phenotypes of differentiated-type adenocarcinomas and precancerous lesions of the stomach are dependent on the genetic pathways. J Pathol 2000;191:257-63.
4. Watters AD, Latif Z, Forsyth A, Dunn I, Underwood MA, Grigor KM, et al. Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer. Br J Cancer 2002;87:654-8.
5. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997;88:435-7.
6. Fujio Y, Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 1999;274:16349-54.
7. Staal SP. Molecular cloning of the akt oncogene and its human homologs Akt1 and Akt2. Amplification of Akt1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci 1987;84:5034-7.
8. Konishi H, Kuroda S, Tanaka M, Matsuzaki H, Ono Y, Kameyama K, et al. Molecular cloning and characterization of a new member of the RAC protein kinase family. Association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins. Biochem Biophys Res Comm 1995;216:526-34.
9. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, et al. Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenecity by antisense RNA. Proc Natl Acad Sci 1996;93:3636-41.
10. Brodbeck D, Cron P, Hemmings BA. A human protein kinase Bγ with regulatory phosphorylation sites in the activation loop and in the C-terminal hydrophobic domain. J Biol Chem 1999;274:9133-6.
11. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ, et al. Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 1999;274:21528-32.
12. Currie RA, Walker KS, Gray A, Deak M, Casamayor A, Downes CP, et al. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J 1999;337:575-83.
13. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
14. Toker A, Newton AC. Akt/Protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem 2000;275:8271-4.
15. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinosotol-3-OH kinase signal transduction. Nature 1995;376:599-602.
16. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995;81:727-36.
17. Duan C, Liimatta MB, Bottum OL. Insulin-like growth factor (IGF)-I regulates IGF-binding protein-5 gene expression through the phosphatidylinositol 3-kinase, protein kinase B/Akt, and p70 S6 kinase signaling pathway. J Biol Chem 1999;274:37147-53.
18. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997;275:1790-2.
19. Porter AC, Vaillancourt RR. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998;16:1343-52.
20. Fukumoto S, Hsieh CM, Maemura K, Layne MD, Yet S-F, Lee KH, et al. Akt participation in the Wnt signaling pathway through Dishevelled. J Biol Chem 2001;276:17479-83.
21. Li J, Yen D, Liaw C, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;28:1943-7.
22. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62.
23. Li DM, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997;57:2124-9.
24. Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 1999;91:1922-32.
25. Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, et al. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/ PTEN. Cancer Res 1999;59:2551-6.
26. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochem Biophys Acta 2000;1470:21-35.
27. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997;57:4997-5000.
28. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58:204-9.
29. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59:4291-6.
30. Yuan ZQ, Sun M, Feldman RI, Wang G, Ma X, Jiang C, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 2000;19:2324-30.
31. Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M, et al. Overexpression of Akt/PKB can modulate chemotherapy-induced apoptosis. Anticancer Res 2000;20:407-16.
32. Itoh N, Semba S, Ito M, Takeda H, Kawata S, Yamakawa M. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002;94:3127-34.
33. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002;86:540-5.
34. Ruggeri BA, Huang L, Wood M, Cheng JQ, Testa JR. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol Carcinog 1998;32:81-6.
35. Lee HS, Lee HK, Kim HS, Yang HK, Kim YI, Kim WH. MUC1, MUC2, MUC5AC, and MUC6 expressions in gastric carcinomas. Cancer 2001;92:1427-34.
36. th edn). Lippincott-Raven: Philadelphia, 1997.
37. Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, et al. Akt proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002;23:201-5.
38. Brennan P, Babbage JW, Burgering BM, Groner B, Reif K. Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F. Immunity 1997;7:679-89.
39. Muise-Helmericks RS, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 1998;273:29864-72.
40. Kang YH, Lee HS, Kim WH. Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 2002;82:285-91.
41. 4L Lee HS, Lee HK, Kim HS, Yang HK, Kim WH. Tumour suppressor gene expression correlates with gastric cancer prognosis. J Pathol 2003;200:39-46.